Peter Hecht, Cyclerion Therapeutics CEO
October 6, 2022 10:35 AM EDT
People
R&D

Iron­wood's for­mer pipeline spin­out hits an­oth­er speed bump, lay­ing off 45% and turn­ing to­ward the mi­to­chon­dria

Max Gelman

Senior Editor

To the cha­grin of the sec­tor, an­oth­er biotech is con­duct­ing lay­offs Thurs­day while mak­ing a some­what sig­nif­i­cant turn — its sec­ond in the last 24 months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times